CLMT

Calumet is a thinly-profitable specialty/fuels refiner sitting on a distressed balance sheet. FY2025 stockholders' equity is NEGATIVE at -$733M against $3.18B of total liabilities and $2.08B of long-term debt, with a -$1.57B accumulated deficit. Liabilities/equity of -4.33x is not a meaningful leverage ratio — it simply signals that book equity has been wiped out, so the $3.11B market cap is paying entirely for forward optionality, not for net assets. The company has lost money in three of the last four years (FY2022 -$173M, FY2024 -$222M, FY2025 -$33.8M), and revenue has drifted down every year since FY2022 ($4.69B → $4.14B). This is poor underlying quality.

The 2025 'improvement' is largely manufactured by items that may not repeat. Operating income of $109M and the narrowed net loss lean heavily on a $114.1M RINs gain that the MD&A attributes to Small Refinery Exemptions received from the EPA in August 2025 — a regulatory benefit the filing explicitly warns 'we have historically received' but is subject to litigation and could be eliminated or narrowed, forcing open-market RIN purchases. Strip out that ~$114M RIN gain and core operations are roughly breakeven to negative on just 5.9% gross margin. A $55.8M gain on the Royal Purple industrial sale further flatters the year. These are liquidity-driven, non-recurring levers, not durable earnings power.